These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38205144)

  • 1. The association between attitudes and the provision of medications for opioid use disorder (MOUD) in United States jails.
    Pfaff A; Cochran A; Vechinski J; Molfenter T; Zayas-Cabán G
    Drug Alcohol Depend Rep; 2024 Mar; 10():100211. PubMed ID: 38205144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives.
    Michener PS; Evans EA; Ferguson WJ; Friedmann PD
    Addict Sci Clin Pract; 2024 Feb; 19(1):10. PubMed ID: 38347634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 and treating incarcerated populations for opioid use disorder.
    Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
    J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
    Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
    Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
    O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
    Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail.
    Bailey A; Senthilkumar R; Evans EA
    J Addict Med; 2023 Sep-Oct 01; 17(5):568-573. PubMed ID: 37788611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the opioid crisis on U.S. state prison systems.
    Scott CK; Dennis ML; Grella CE; Mischel AF; Carnevale J
    Health Justice; 2021 Jul; 9(1):17. PubMed ID: 34304335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing provision of MOUD and obstetric care in U.S. jails: A content analysis of policies submitted by 59 jails.
    Kao L; Lee C; Parayil T; Kramer C; Sufrin CB
    Drug Alcohol Depend; 2023 Jul; 248():109877. PubMed ID: 37244223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
    Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
    Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitators and barriers to adopting or expanding medications for opioid use disorder provision in rural Colorado jails: a qualitative analysis.
    McNeely HL; Schreiber TL; Swann WL; Amura CR
    Health Justice; 2024 Jun; 12(1):26. PubMed ID: 38842589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
    Pasman E; Lee G; Kollin R; Rodriguez B; Agius E; Madden EF; Resko SM
    Subst Use Misuse; 2022; 57(12):1828-1836. PubMed ID: 36041008
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.